Skip directly to content

Minimize RSR Award Detail

Research Spending & Results

Award Detail

Awardee:OPTIMEOS LIFE SCIENCES, INC.
Doing Business As Name:Optimeos Life Sciences, Inc.
PD/PI:
  • Robert Pagels
  • (443) 631-2431
  • rpagels@optimeos.com
Co-PD(s)/co-PI(s):
  • Robert K Prud'homme
Award Date:01/05/2021
Estimated Total Award Amount: $ 256,000
Funds Obligated to Date: $ 256,000
  • FY 2021=$256,000
Start Date:12/15/2020
End Date:08/31/2021
Transaction Type:Grant
Agency:NSF
Awarding Agency Code:4900
Funding Agency Code:4900
CFDA Number:47.041
Primary Program Source:040100 NSF RESEARCH & RELATED ACTIVIT
Award Title or Description:STTR Phase I: Formulation of a COVID-19 mRNA Vaccine by Inverse Flash NanoPrecipitation
Federal Award ID Number:2032023
DUNS ID:964021369
Program:STTR Phase I
Program Officer:
  • Kaitlin Bratlie
  • (703) 292-2638
  • kbratlie@nsf.gov

Awardee Location

Street:174 Nassau St, Suite 334
City:Princeton
State:NJ
ZIP:08542-7005
County:Princeton
Country:US
Awardee Cong. District:12

Primary Place of Performance

Organization Name:Optimeos Life Sciences, Inc.
Street:303A College Rd E
City:Princeton
State:NJ
ZIP:08540-6608
County:Princeton
Country:US
Cong. District:12

Abstract at Time of Award

The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is the development of a novel messenger ribonucleic acid (mRNA)-based vaccine for COVID-19. The fastest-to-clinic vaccine for COVID-19 was mRNA-based; however, there are no mRNA-based vaccines on the market currently. This is, in part, because this class of vaccines is difficult to optimize and manufacture at a large scale. If clinical trials are successful, hundreds of millions of doses will be needed in the U.S. alone. This STTR project aims to pioneer a novel technique to manufacture mRNA-based vaccines initially for COVID-19. This technology is highly modular, allowing for the better understanding and optimization of this class of vaccines. Importantly, this new technique can be scaled to manufacture the doses needed both for the current COVID-19 pandemic and in the case of future outbreaks. The flexibility and scalability of this platform technology provide a durable competitive advantage. Following demonstration of preclinical efficacy, the company will work with an established pharmaceutical partner for testing and manufacturing. Capturing 5% of the U.S. COVID-19 vaccine market would bring an estimated $125 million in revenue. This is a beachhead market, and, once successful, the company will expand into other mRNA-based vaccine and therapeutic markets. This Small Business Technology Transfer (STTR) Phase I project aims to develop an mRNA-based nanoparticle vaccine for COVID-19 without the use of cationic materials. Current formulation methods require cationic lipids or polymers to form charge-based complexes with the anionic mRNA. Charge-based assembly limits the accessible nanoparticle surface chemistries, a feature crucial to directing which cell types will be transfected and the resulting immune response. Additionally, mRNA is only a minor component of the resulting formulations. The proposed formulation method decouples the mRNA encapsulation from the nanoparticle surface in a two-step process. The method does not require cationic materials, allowing for mRNA loadings up to 5-times higher than those achievable through other routes. However, mRNA transfection has not previously been demonstrated without the use of cationic materials. This will be achieved by completing three key milestones: (1) optimize mRNA encapsulation, (2) vary surface coatings to enhance dendritic cell uptake, and (3) demonstrate efficient cell transfection. A highly loaded nanoparticle formulation that can efficiently target and transfect dendritic cells is desired. Following the completion of this Phase I work, this formulation may be applied to a SARS-CoV-2 spike protein-coding mRNA to produce a COVID-19 vaccine. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

For specific questions or comments about this information including the NSF Project Outcomes Report, contact us.